[
  {
    "objectID": "quarto/main.html",
    "href": "quarto/main.html",
    "title": "The Financial Toxicity of Universal SGLT2i in HF",
    "section": "",
    "text": "— CONSORT FLOW DIAGRAM DATA (Person-Years) —\nSTEP 1: Total MEPS Population (2021-2023) | N = 69,686\nExclusion 1: No HF Diagnosis | n = 69,141\nSTEP 2: Heart Failure Diagnosis (CCSR: CIR019) | N = 545 (0.8%)\nExclusion 2: Pediatric &lt; 18 | n = 0 (0.0%)\nSTEP 3: Adult Population (Age &gt;= 18) | N = 545 (100.0%)\nExclusion 3: No GDMT Exclusion (Universal Sample Retained) | n = 0\nSTEP 4: Broad HF Cohort | N = 545 (100.0%)\nExclusion 4: Uninsured/Other | n = 12 (2.2%)\nSTEP 5: Final Analytic Cohort (Valid Insurance) | N = 533 (97.8%)\n\n\n\n\n\n\n\nTable 1. Weighted Baseline Demographic and Clinical Characteristics of the U.S. Heart Failure Population (MEPS 2021–2023).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 1,833,138 (100%)1\nCommercial N = 167,779 (9.2%)1\nMedicaid/Dual N = 582,020 (32%)1\nMedicare N = 1,083,339 (59%)1\n\n\n\n\nAge Category\n\n\n\n\n\n\n\n\n\n\n    &lt;65\n610,131 (33%)\n167,779 (100%)\n367,772 (63%)\n74,580 (6.9%)\n\n\n    65-74\n421,899 (23%)\n0 (0%)\n117,246 (20%)\n304,653 (28%)\n\n\n    75+\n801,109 (44%)\n0 (0%)\n97,003 (17%)\n704,106 (65%)\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n    Male\n840,041 (46%)\n110,333 (66%)\n222,755 (38%)\n506,953 (47%)\n\n\n    Female\n993,097 (54%)\n57,446 (34%)\n359,266 (62%)\n576,386 (53%)\n\n\nRace/Ethnicity\n\n\n\n\n\n\n\n\n\n\n    White\n1,336,511 (73%)\n89,572 (53%)\n353,994 (61%)\n892,945 (82%)\n\n\n    Black\n310,743 (17%)\n57,469 (34%)\n132,585 (23%)\n120,688 (11%)\n\n\n    Hispanic\n90,137 (4.9%)\n0 (0%)\n49,229 (8.5%)\n40,909 (3.8%)\n\n\n    Other\n95,747 (5.2%)\n20,738 (12%)\n46,213 (7.9%)\n28,797 (2.7%)\n\n\nIncome Tier\n\n\n\n\n\n\n\n\n\n\n    Low\n780,289 (43%)\n25,239 (15%)\n396,151 (68%)\n358,899 (33%)\n\n\n    Mid\n541,851 (30%)\n69,908 (42%)\n120,024 (21%)\n351,918 (32%)\n\n\n    High\n510,999 (28%)\n72,632 (43%)\n65,845 (11%)\n372,522 (34%)\n\n\nCurrent SGLT2i Use\n242,314 (13%)\n32,709 (19%)\n72,502 (12%)\n137,103 (13%)\n\n\n\n1 n (%)\n\n\nNotes: Data derived from the Medical Expenditure Panel Survey (MEPS), pooled 2021–2023. Values represent weighted national estimates. ‘Income Tier’ is based on poverty line thresholds (&lt;125% Low, 125-400% Mid, &gt;400% High).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2. Breakdown of Annual Out-of-Pocket Healthcare Expenditures by Category and Demographic Subgroup (2023 Inflation-Adjusted Dollars).\n\n\n\n\n\n\n\n\n\n\nTotal Out-of-Pocket Costs\nMedications (OOP)\nPremiums (OOP)\nOutpatient/Office (OOP)\nInpatient (OOP)\n\n\n\n\nOverall Population\n\n\nOverall\n$1818 (1436-2303)\n$423 (352-508)\n$888 (601-1311)\n$416 (274-633)\n$92 (65-130)\n\n\nInsurance Type\n\n\nCommercial\n$4852 (2744-8582)\n$333 (216-512)\n$3248 (1668-6325)\n$1079 (509-2284)\n$193 (71-529)\n\n\nMedicaid/Dual\n$600 (291-1237)\n$102 (69-150)\n$322 (87-1192)\n$127 (47-345)\n$49 (21-116)\n\n\nMedicare\n$2003 (1594-2517)\n$609 (504-737)\n$826 (522-1306)\n$469 (287-765)\n$99 (65-149)\n\n\nAge Group\n\n\n&lt;65\n$1815 (1052-3132)\n$198 (144-273)\n$1112 (557-2220)\n$403 (195-832)\n$102 (51-206)\n\n\n65-74\n$2002 (1218-3291)\n$584 (436-782)\n$980 (422-2277)\n$364 (148-894)\n$74 (40-138)\n\n\n75+\n$1724 (1345-2209)\n$509 (386-672)\n$668 (425-1050)\n$454 (246-837)\n$93 (57-153)\n\n\nSex\n\n\nMale\n$1824 (1376-2419)\n$452 (337-607)\n$948 (604-1490)\n$321 (179-575)\n$103 (66-159)\n\n\nFemale\n$1813 (1243-2646)\n$398 (311-509)\n$836 (442-1583)\n$497 (290-850)\n$82 (46-147)\n\n\nIncome Level\n\n\nLow\n$1161 (840-1605)\n$315 (247-402)\n$485 (243-967)\n$269 (146-497)\n$92 (51-168)\n\n\nMid\n$1754 (1288-2389)\n$468 (352-623)\n$798 (486-1308)\n$403 (201-806)\n$85 (51-142)\n\n\nHigh\n$2890 (1878-4447)\n$539 (394-739)\n$1598 (850-3001)\n$655 (340-1262)\n$98 (45-213)\n\n\nRace/Ethnicity\n\n\nWhite\n$1780 (1394-2275)\n$443 (373-526)\n$787 (517-1199)\n$459 (287-731)\n$91 (62-135)\n\n\nBlack\n$2087 (913-4771)\n$394 (185-841)\n$1370 (506-3706)\n$237 (67-838)\n$87 (26-287)\n\n\nHispanic\n$1940 (664-5670)\n$412 (122-1398)\n$782 (117-5238)\n$646 (72-5820)\n$99 (15-641)\n\n\nOther\n$1360 (757-2442)\n$243 (112-526)\n$820 (373-1801)\n$190 (34-1071)\n$107 (29-396)\n\n\n\nNotes: Values represent mean annual out-of-pocket (OOP) expenditures. Confidence intervals (95%) were calculated using bootstrap-estimated standard errors (1000 replicates) and log-transformation to account for the right-skewed distribution of healthcare costs. Outliers capped at the 99th percentile for variance stabilization. Wide confidence intervals in smaller subgroups reflect the inherent high variance of OOP expenditures in the U.S. healthcare system, where a small proportion of patients incur the majority of costs.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 3. Projected Incidence of Financial Toxicity Among Medicare Beneficiaries Under Universal SGLT2i and Post-IRA Policy Scenarios.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n29.4 (22.3-37.7)\n34.2 (26.5-42.7)\n32.3 (24.5-41.2)\n1.9\n5.4\n\n\nAge Group\n\n\n&lt;65\n26.6 (NR)\n42.4 (NR)\n42.4 (NR)\n0.0\n0.0\n\n\n65-74\n26.8 (16.2-40.8)\n31.1 (20.2-44.5)\n29.7 (19.0-43.3)\n1.3\n4.3\n\n\n75+\n30.9 (22.1-41.3)\n34.6 (25.1-45.5)\n32.4 (22.9-43.6)\n2.3\n6.6\n\n\nSex\n\n\nMale\n23.5 (15.4-34.1)\n30.4 (20.4-42.7)\n27.2 (17.2-40.2)\n3.2\n10.6\n\n\nFemale\n34.7 (24.5-46.6)\n37.5 (27.1-49.1)\n36.8 (26.5-48.5)\n0.7\n1.7\n\n\nIncome Level\n\n\nLow\n64.9 (45.2-80.5)\n76.7 (54.3-90.1)\n75.6 (53.8-89.2)\n1.1\n1.5\n\n\nMid\n23.4 (12.4-39.7)\n25.9 (15.0-40.8)\n22.4 (12.9-36.0)\n3.5\n13.5\n\n\nHigh\n1.0 (NR)\n1.0 (NR)\n0.0 (NR)\n1.0\n100.0\n\n\nRace/Ethnicity\n\n\nWhite\n25.6 (18.1-34.8)\n31.2 (22.9-40.9)\n30.6 (22.3-40.3)\n0.6\n2.0\n\n\nBlack\n49.7 (30.0-69.5)\n50.5 (30.7-70.2)\n38.4 (16.6-66.1)\n12.1\n24.0\n\n\nHispanic\n43.4 (NR)\n43.4 (NR)\n43.4 (NR)\n0.0\n0.0\n\n\nOther\n44.7 (NR)\n44.7 (NR)\n44.7 (NR)\n0.0\n0.0\n\n\n\nNotes: Financial Toxicity is defined as annual medical expenditures (including premiums) exceeding 20% of post-subsistence income. ‘Universal SGLT2i’ assumes 100% adherence to guideline-directed therapy. ‘Post-IRA’ applies a $2,000 annual pharmacy cap to the Medicare Part D portion. CIs calculated using Logit-transformed intervals based on bootstrap standard errors (1000 replicates). ‘NR’ = Not reported due to insufficient degrees of freedom. ‘-’ = Value suppressed due to small sample size or insufficient event counts.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 4. Policy Efficiency Metrics: Economic Number Needed to Harm/Treat (NNH/NNT) and Projected Annual Lives Protected.\n\n\n\n\n\n\n\n\n\n\neNNH (Universal SGLT2i vs Baseline)\neNNT (Post-IRA vs Universal SGLT2i)\nLives Protected (Annual Count)\n\n\n\n\nOverall\n\n\nOverall\n21\n54\n20,061\n\n\nAge Group\n\n\n&lt;65\n6\nNegl.\n0\n\n\n65-74\n23\n75\n4,062\n\n\n75+\n27\n44\n15,999\n\n\nSex\n\n\nMale\n14\n31\n16,312\n\n\nFemale\n36\n154\n3,749\n\n\nIncome Level\n\n\nLow\n8\n88\n4,062\n\n\nMid\n40\n29\n12,250\n\n\nHigh\nNegl.\n99\n3,749\n\n\nRace/Ethnicity\n\n\nWhite\n18\n164\n5,442\n\n\nBlack\n132\n8\n14,619\n\n\nHispanic\nNegl.\nNegl.\n0\n\n\nOther\nNegl.\nNegl.\n0\n\n\n\nNotes: ‘eNNH’ = Economic Number Needed to Harm (number of patients prescribed Universal SGLT2i to cause one new case of toxicity). ‘eNNT’ = Economic Number Needed to Treat (number of patients benefiting from the IRA cap to prevent one case of toxicity). ‘Lives Protected’ = Absolute Risk Reduction × Population Size. ‘Negl.’ = Negligible risk difference (&lt;0.5%).\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1. Impact of Universal SGLT2i Adherence and IRA Provisions on Financial Toxicity and Cost Composition Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nFigure 2. Reductions in Financial Toxicity by Demographic Subgroup Under the Inflation Reduction Act.\n\n\n\n\n\n\n\n\n\n\nFigure 3. Insurance Coverage Distribution Across Subgroups: Explaining the Differential Impact of IRA Policy.\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 1. Annualized Median Out-of-Pocket Costs for SGLT2i by Insurance Type (2023 Inflation-Adjusted Dollars).\n\n\n\n\n\n\n\n\n\nInsurance Plan\nAnnual SGLT2i Cost\n\n\n\n\nMedicare\n$532\n\n\nMedicaid/Dual\n$0\n\n\nCommercial\n$91\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 2. Projected Annual Out-of-Pocket Savings for Medicare Beneficiaries Stratified by Income Level.\n\n\n\n\n\n\n\n\n\nIncome Level\nPre-IRA OOP ($)\nPost-IRA OOP ($)\nNet Annual Savings ($)\n% Benefiting\nSavings (Among Beneficiaries Only, $)\n\n\n\n\nOverall\n$3,893\n$3,608\n$285\n13.1\n$2,179\n\n\nLow\n$3,000\n$2,708\n$292\n12.2\n$2,391\n\n\nMid\n$4,309\n$4,031\n$278\n13.9\n$1,998\n\n\nHigh\n$4,361\n$4,077\n$284\n13.1\n$2,170\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 3. Sensitivity Analysis: Projected Financial Toxicity (FT) in the Overall U.S. HF Population (Including Commercial and Medicaid). Note: Impact is diluted as ~40% of the population (Commercial/Medicaid) is ineligible for the IRA cap.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Patients\n31.8 (25.5-38.7)\n34.5 (27.9-41.8)\n33.4 (26.8-40.8)\n1.1\n3.2\n\n\nAge Group\n\n\n&lt;65\n32.6 (22.7-44.2)\n34.5 (24.1-46.6)\n34.5 (24.1-46.6)\n0.0\n0.0\n\n\n65-74\n28.7 (18.3-42.0)\n31.8 (21.0-45.0)\n30.8 (20.1-44.2)\n1.0\n3.0\n\n\n75+\n32.8 (24.6-42.1)\n36.0 (27.4-45.7)\n34.0 (25.3-44.0)\n2.0\n5.5\n\n\nSex\n\n\nMale\n24.9 (17.6-34.1)\n29.1 (20.4-39.6)\n27.2 (18.5-38.0)\n1.9\n6.7\n\n\nFemale\n37.5 (29.4-46.5)\n39.1 (31.0-48.0)\n38.8 (30.6-47.6)\n0.4\n1.0\n\n\nIncome Level\n\n\nLow\n61.6 (50.0-72.1)\n67.1 (55.0-77.2)\n66.5 (54.6-76.7)\n0.5\n0.8\n\n\nMid\n15.8 (8.4-27.8)\n17.5 (10.1-28.4)\n15.2 (8.9-24.8)\n2.3\n13.0\n\n\nHigh\n3.0 (NR)\n3.0 (NR)\n2.3 (NR)\n0.7\n24.5\n\n\nRace/Ethnicity\n\n\nWhite\n26.7 (19.8-34.8)\n30.4 (23.1-38.9)\n30.0 (22.7-38.5)\n0.4\n1.3\n\n\nBlack\n47.5 (31.5-64.0)\n47.8 (31.8-64.3)\n43.1 (26.5-61.4)\n4.7\n9.8\n\n\nHispanic\n44.0 (NR)\n44.0 (NR)\n44.0 (NR)\n0.0\n0.0\n\n\nOther\n40.0 (NR)\n40.0 (NR)\n40.0 (NR)\n0.0\n0.0\n\n\nInsurance Type\n\n\nCommercial\n17.3 (4.9-45.9)\n17.3 (4.9-45.9)\n17.3 (4.9-45.9)\n0.0\n0.0\n\n\nMedicaid/Dual\n40.2 (29.0-52.6)\n40.2 (29.0-52.6)\n40.2 (29.0-52.6)\n0.0\n0.0\n\n\nMedicare\n29.4 (22.3-37.7)\n34.2 (26.5-42.7)\n32.3 (24.5-41.2)\n1.9\n5.4\n\n\n\nNotes: CIs calculated using Logit-transformed intervals based on bootstrap standard errors (1000 replicates). ‘NR’ = Not reported due to insufficient degrees of freedom. ‘-’ = Value suppressed due to small sample size or insufficient event counts.\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 4. Projected Incidence of Catastrophic Financial Toxicity (&gt;40% of Income) Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n21.0 (14.7-29.0)\n21.4 (15.0-29.4)\n19.7 (13.5-27.9)\n1.7\n7.7\n\n\nAge Group\n\n\n&lt;65\n23.9 (NR)\n23.9 (NR)\n23.9 (NR)\n0.0\n0.0\n\n\n65-74\n18.9 (9.3-34.5)\n18.9 (9.3-34.5)\n18.1 (8.7-33.8)\n0.8\n4.1\n\n\n75+\n21.6 (14.1-31.5)\n22.2 (14.5-32.3)\n20.0 (12.6-30.0)\n2.2\n10.0\n\n\nSex\n\n\nMale\n20.3 (12.5-31.2)\n21.1 (13.2-31.9)\n17.8 (10.5-28.7)\n3.3\n15.4\n\n\nFemale\n21.6 (13.1-33.4)\n21.6 (13.1-33.4)\n21.3 (12.9-33.2)\n0.2\n1.1\n\n\nIncome Level\n\n\nLow\n56.3 (38.8-72.5)\n56.3 (38.8-72.5)\n54.8 (37.4-71.0)\n1.6\n2.8\n\n\nMid\n7.1 (NR)\n8.3 (0.4-69.7)\n4.8 (NR)\n3.5\n42.0\n\n\nHigh\n0.0 (NR)\n0.0 (NR)\n0.0 (NR)\n0.0\n-\n\n\nRace/Ethnicity\n\n\nWhite\n16.0 (10.2-24.2)\n16.4 (10.5-24.7)\n16.2 (10.4-24.5)\n0.2\n1.0\n\n\nBlack\n48.6 (28.9-68.7)\n48.6 (28.9-68.7)\n34.9 (14.5-62.9)\n13.7\n28.1\n\n\nHispanic\n32.7 (NR)\n32.7 (NR)\n32.7 (NR)\n0.0\n0.0\n\n\nOther\n44.7 (NR)\n44.7 (NR)\n44.7 (NR)\n0.0\n0.0\n\n\n\nNotes: Catastrophic toxicity defined as annual person-level medical expenditures (including premiums) exceeding 40% of post-subsistence family income. ‘-’ = Value suppressed due to small sample size or insufficient event counts.\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Figure 1. Reductions in Catastrophic Financial Toxicity (&gt;40%) by Demographic Subgroup."
  }
]